|
|
|
|
| LEADER |
01889nmm a2200289 u 4500 |
| 001 |
EB000629753 |
| 003 |
EBX01000000000000000482835 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9781468472752
|
| 100 |
1 |
|
|a De Clercq, Erik
|e [editor]
|
| 245 |
0 |
0 |
|a Antiviral Drug Development
|h Elektronische Ressource
|b A Multidisciplinary Approach
|c edited by Erik De Clercq, Richard T. Walker
|
| 250 |
|
|
|a 1st ed. 1988
|
| 260 |
|
|
|a New York, NY
|b Springer US
|c 1988, 1988
|
| 300 |
|
|
|a VIII, 314 p. 13 illus
|b online resource
|
| 505 |
0 |
|
|a Antiviral Chemotherapy: An Introduction and Reasons for the Slow Progress, Particularly towards Rational Design -- Design of Nucleoside Analogs as Potential Antiviral Agents -- Design of Anti-Viral Agents other than Nucleoside Analogues -- Antivirals for High Hazards Viruses -- Human Retroviruses and Anti-Viral Therapies -- Epstein-Barr Virus -- Molecular Targets for Selective Antiviral Chemotherapy -- Inhibition of S-Adenosylmethionine-Dependent Transmethylation as an Approach to the Development of Antiviral Agents -- Assay Systems: Testing of Antiviral Drugs in Cell Culture (in vitro) -- Animal Models as Assay Systems for the Development of Antivirals -- Experimental Aspects of Antiviral Pharmacology -- Virus Drug Resistance -- Interferon as an Antiviral Agent -- Risk-Benefit Analysis in Drug Research -- Safety Assessment of Antiviral Drugs -- Antiviral Agents: A New Beginning -- Participants
|
| 653 |
|
|
|a Virology
|
| 653 |
|
|
|a Diseases
|
| 653 |
|
|
|a Pharmacology
|
| 700 |
1 |
|
|a Walker, Richard T.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a NATO Science Series A:, Life Sciences
|
| 028 |
5 |
0 |
|a 10.1007/978-1-4684-7275-2
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-4684-7275-2?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 615
|